Design and synthesis of a beta-lactamase activated 5-fluorouracil prodrug.
Ryan M Phelan, Marc Ostermeier, Craig A Townsend
Index: Bioorg. Med. Chem. Lett. 19(4) , 1261-3, (2009)
Full Text: HTML
Abstract
An efficient synthesis of a 5-fluorouracil-cephalosporin prodrug is described for use against colorectal and other cancers in antibody and gene-directed therapies. The compound shows stability in aqueous media until specifically activated by beta-lactamase (betaL). The kinetic parameters of the 5-fluorouracil-cephalosporin conjugate were determined in the presence of Enterobacter cloacae P99 betaL (ECl betaL) revealing a K(m)=95.4 microM and V(max)=3.21 microMol min(-1) mg(-1). The data compare favorably to related systems that have been reported and enable testing of this prodrug against cancer cell lines in vitro and in vivo.
Related Compounds
Related Articles:
A Novel Microbisporicin Producer Identified by Early Dereplication during Lantibiotic Screening.
2015-01-01
[Biomed Res. Int. 2015 , 419383, (2015)]
Identification of peptide inhibitors of penicillinase using a phage display library.
2016-02-01
[Anal. Biochem. 494 , 4-9, (2015)]
2014-03-01
[J. Med. Microbiol. 63(Pt 3) , 386-92, (2014)]
2012-11-01
[J. Assoc. Physicians India 60 , 22-4, (2012)]
2013-01-01
[Przegl. Epidemiol. 67(1) , 51-6, 135-40, (2013)]